Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Rheumatology
Reference14 articles.
1. Ceccarelli F, Natalucci F, Olivieri G, Perricone C, Pirone C, Spinelli FR, Alessandri C, Conti F (2021) Erosive arthritis in systemic lupus erythematosus: not only Rhupus. Lupus 30:2029–2041. https://doi.org/10.1177/09612033211051637
2. Piga M, Saba L, Gabba A, Congia M, Balestrieri A, Mathieu A, Cauli A (2016) Ultrasonographic assessment of bone erosions in the different subtypes of systemic lupus erythematosus arthritis: comparison with computed tomography. Arthritis Res Ther 18:222. https://doi.org/10.1186/s13075-016-1125-8
3. Antonini L, Le Mauff B, Marcelli C, Aouba A, de Boysson H (2020) Rhupus: a systematic literature review. Autoimmun Rev 19:102612. https://doi.org/10.1016/j.autrev.2020.102612
4. Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D’Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA, BLISS-52 and BLISS-76 Study Groups (2012) Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 71:1833–1838. https://doi.org/10.1136/annrheumdis-2011-200831
5. Ceccarelli F, Cipriano E, Natalucci F, Perricone C, Olivieri G, Orefice V, Morello F, Alessandri C, Spinelli FR, Conti F (2020) Belimumab is Able to Induce a Significant Improvement of Joint Activity Status in Patients Diagnosed with Systemic Lupus Erythematosus: Results From a 12-Month Longitudinal Study. Isr Med Assoc J IMAJ 22:415–419